Search Results

Your search for Christopher Hoimes, MD,Christopher Hoimes, MD matches 2 pages

Showing 1 - 2

By Matthew Stenger / August 25, 2023 - Supplement: Genitourinary Oncology Almanac

Enfortumab Vedotin-ejfv Plus Pembrolizumab in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer

In a phase Ib/II study reported in the Journal of Clinical Oncology, Christopher J. Hoimes, MD, and colleagues found that first-line enfortumab vedotin-ejfv plus pembrolizumab produced a high response rate and prolonged response durations in cisplatin-ineligible, previously untreated patients with...

solid tumors

By Christopher Hoimes, MD / July 10, 2021

Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer

The first known clinical trial report of an antibody-drug conjugate was a phase 0/I pharmacodynamic and safety study of a conjugate that targeted carcinoembryonic antigen and delivered a payload of vinca alkaloid in eight patients with ovarian or colorectal cancer.1 This work built on the work of...

Jul

Today In Oncology

Search Results

Your search for Christopher Hoimes, MD,Christopher Hoimes, MD matches 2 pages

Enfortumab Vedotin-ejfv Plus Pembrolizumab in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer

Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer

Addition of Glofitamab to R-CHOP or Pola-R-CHP in Younger Patients With High-Risk LBCL

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

PPP2R1A Mutations Linked to Improved Immunotherapy Outcomes in Ovarian Clear Cell Carcinoma

Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer